Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



New Products

More »
Aug 1, 2012 (Vol. 32, No. 14)

Binding Site

Click Image To Enlarge +

RF/IgG Absorbent Reagent

Specifically designed for use in conjunction with immunodiagnostic assays, the RF/IgG absorbent reagent is formulated to remove both IgG and RF-IgM molecules from human serum. The reagent can prevent these bodily components from nonspecific binding within the test sample. It can also enhance overall specificity by reducing both the number of false positive test results from native IgG components and the number of false negative test results from native RF-IgM components. The reagent is available as a ready-to-use, fully liquid stable product and is offered in a number of operator-oriented packaging configurations including bulk-sized formats.

Specifically designed for use in conjunction with immunodiagnostic assays, the RF/IgG absorbent reagent is formulated to remove both IgG and RF-IgM molecules from human serum. The reagent can prevent these bodily components from nonspecific binding within the test sample. It can also enhance overall specificity by reducing both the number of false positive test results from native IgG components and the number of false negative test results from native RF-IgM components. The reagent is available as a ready-to-use, fully liquid stable product and is offered in a number of operator-oriented packaging configurations including bulk-sized formaSpecifically designed for use in conjunction with immunodiagnostic assays, the RF/IgG absorbent reagent is formulated to remove both IgG and RF-IgM molecules from human serum. The reagent can prevent these bodily components from nonspecific binding within the test sample. It can also enhance overall specificity by reducing both the number of false positive test results from native IgG components and the number of false negative test results from native RF-IgM components. The reagent is available as a ready-to-use, fully liquid stable product and is offered in a number of operator-oriented packaging configurations including bulk-sized formats.

 

  • Binding Site
  • 5889 Oberlin Drive #101
  • San Diego, CA, 92121
  • UNITED STATES

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll